

# Global University and Chula S.I.M Strategy On Research Ecosystem

*Professor Kiat Ruxrungtham*  
*Vice President for Research and Innovation*

# Research and Innovation for Society

100  
YEARS  
THE CENTENNIAL  
CELEBRATIONS  
OF  
CHULALONGKORN  
UNIVERSITY

## Global University and Chula S.I.M Strategy On Research Ecosystem

**Kiat Ruxrungtham**

Vice President for Research, Innovation  
Professor of Medicine  
Chulalongkorn University



# Ultimate Goals of *the University*



สร้าง  
คน

คนคุณภาพ

ความรู้  
นวัตกรรม

ให้แก่โลก

ประโยชน์

ต่อประเทศ  
ต่อโลก

\*photo is from [www.bakermckenzie.com](http://www.bakermckenzie.com)



# Why are you a Chula Faculty ?



สร้างคน  
**Student  
Development**



สร้างประโยชน์  
แก่สังคม  
**Betterment  
of the Society**

- Social Impact
- Industrial Impact
- Cultural Impact
- Global Impact



# Global University vs Ranking

## 1 Global rankings

- 1.1 [Academic Ranking of World Universities](#)
- 1.2 [Center for World University Rankings](#)
- 1.3 [Eduniversal](#)
- 1.4 [G-factor](#)
- 1.5 [Global University Ranking](#)
- 1.6 [HEEACT—Ranking of Scientific Papers](#)
- 1.7 [Human Resources & Labor Review](#)
- 1.8 [High Impact Universities: Research Performance Index](#)
- 1.9 [Leiden Ranking](#)
- 1.10 [Nature Index](#)
- 1.11 [Newsweek](#)
- 1.12 [Professional Ranking of World Universities](#)
- 1.13 [QS World University Rankings](#)
  - 1.13.1 [QS Asian University Rankings](#)
  - 1.13.2 [QS Latin American University Rankings](#)
- 1.14 [Reuters World's Top 100 Innovative Universities](#)
- 1.15 [Round University Ranking](#)
- 1.16 [SCImago Institutions Rankings](#)
- 1.17 [Times Higher Education World University Rankings](#)
  - 1.17.1 [Times Higher Education World Reputation Rankings](#)
- 1.18 [U-Multirank](#)
- 1.19 [UniRanks "The Ranking of Rankings"](#)
- 1.20 [University Ranking by Academic Performance](#)
- 1.21 [U.S. News & World Report's Best Global Universities Rankings](#)
- 1.22 [Webometrics](#)
- 1.23 [Wuhan University](#)




No Any Ranking System is Perfect  
Almost all reflecting  
**quality of research > quality of HE**

How to **transform**  
our **U**niversity ?

# Transforming the University in Thailand

- **Leader Recruitment**  
with **full authority**
  - World Renowned
  - Policy/Mission driven
- **High funding**
  - Government
  - Endowment
  - Donation
- **Performance-based evaluation**
- **High proportion of international staffs**
- **High proportion of international students**



- **Leader Recruitment**  
with **partial authority**
  - popularity recruitment
  - compromising
- **Limited funding**
  - Government (low, uncertainty)
  - Endowment
  - Donation (inefficient)
- **Performance-based evaluation –can't be done**
- **Low proportion of international staffs**
- **Low proportion of international students**

So we must transform smartly  
under the Thai system context



# University Leadership

Organisation **University Leadership**

## Professor Subra Suresh



from



**Professor Subra Suresh**  
**NTU President**

Professor Subra Suresh is an eminent American scientist, engineer and entrepreneur with decades of distinguished and impactful leadership in academia, industry and government. He was appointed president of NTU in July 2017 and began his tenure on 1st January, 2018. In recognition of his scholarly and scientific achievements in research, the NTU Board of Trustees also selected him as the inaugural *Distinguished University Professor*, the highest honour given to a faculty member at NTU.

He was the ninth President of Carnegie Mellon University (CMU) from 2013 to 2017. Before that, he served as Director of the US National Science Foundation (NSF) from 2010 to 2013, and Dean of the School of Engineering from 2007 to 2010 at the Massachusetts Institute of Technology (MIT), where he was a faculty member for two decades.

02 | NTU ANNUAL REPORT 2017

### AT A GLANCE

#### GLOBAL



**111**  
nationalities  
on campus

**573**  
university partners in  
academia and research

**32**  
joint entities set up with  
leading multinationals  
on campus

**350**  
partner universities in  
close to 45 countries  
offer student attachment  
programmes

**7 in 10**  
undergraduates have  
an overseas opportunity  
during their studies

**26**  
joint/dual PhD degree  
programmes with  
overseas universities

#### HONOURS



**1st**  
in QS ranking of  
the world's young  
universities for 4<sup>th</sup>  
consecutive year

**4th**  
in Times Higher  
Education Asia University  
Rankings 2017, up 6  
places from 2015

**52nd**  
in Times Higher  
Education World  
University Rankings  
2017, up 122 places  
since 2011

**11th**  
in QS World University  
Rankings 2017/18

**4th**  
in Engineering and  
Technology in QS World  
University Rankings  
2017/18

**Research**  
**budget 2017 :**  
**426 M \$ =**  
**14,000 MB**

# Chula Strategies Improving **Research Quality & Impact**

สำนักบริหารการวิจัย  
Research Affair Office

6M/5M

Pain points Rx with  
**F. E. B.**  
Faster. Easier. Better.





# Key CU Research Strategies

*implemented in the **past 3 years***

## **1. Publication awards policy**

- For **Tier 1** (Top 10% J) and **Q1** (Top 25% J) only


## **2. Increase > double number of STAR/RU/CEs**

- Enhancing research team works

## **3. Increase number of Post-doc**

## **4. International Research Forum**


- Enhancing strategic partners, co-publication, joint researches



# Output from doubling # STAR, RU, CE

## Output last 2 years (mid 2017-2019)

- Tier 1 (89) + Q1 (120) = **209** papers
- Co-publication: **148** papers
- External Grants: 173+9 = **182**







# 28 Faculties/Institutes have STAR/RU/CE

	STAR			RU			CE			Total
	ก่อนรับ ตำแหน่ง	หลังรับ ตำแหน่ง (ตั้งแต่ พ.ค 59)	รวม	ก่อนรับ ตำแหน่ง	หลังรับ ตำแหน่ง (ตั้งแต่ พ.ค 59)	รวม	ก่อนรับ ตำแหน่ง	หลังรับ ตำแหน่ง (ตั้งแต่ พ.ค 59)	รวม	
คณะแพทยศาสตร์	2	8	10	15	21	36	5	9	14	60
คณะสัตวแพทยศาสตร์	4	2	6	6	7	13	1	0	1	20
คณะเภสัชศาสตร์	0	2	2	6	6	12	1	0	1	15
คณะทันตแพทยศาสตร์	0	1	1	4	4	8	0	0	0	9
คณะสหเวชศาสตร์	1	3	4	0	2	2	0	0	0	6
คณะวิทยาศาสตร์	2	11	13	22	10	32	7	5	12	57
คณะวิทยาศาสตร์การกีฬา	0	1	1	0	0	0	0	0	0	1
คณะพยาบาลศาสตร์	0	4	4	0	0	0	0	0	0	4
คณะวิศวกรรมศาสตร์	3	5	8	16	12	28	6	3	9	45
คณะสถาปัตยกรรมศาสตร์	0	0	0	1	3	4	1	2	3	7
คณะนิเทศศาสตร์	0	0	0	0	2	2	0	0	0	2
คณะพาณิชยศาสตร์และการบัญชี	0	0	0	0	2	2	0	0	0	2
คณะครุศาสตร์	0	1	1	0	4	4	0		0	5
คณะรัฐศาสตร์	0	0	0	1	0	1	0	1	1	2
คณะเศรษฐศาสตร์	0	0	0	0	0	0	1	0	1	1
คณะอักษรศาสตร์	0	3	3	3	3	6	1	0	1	10
คณะศิลปกรรมศาสตร์	0	0	0	1	2	3	1	0	1	4
คณะจิตวิทยา	0	2	2	0	0	0	0	0	0	2
วิทยาลัยปิโตรเลียมและปิโตรเคมี	0	1	1	5	1	6	0	0	0	7
วิทยาลัยวิทยาศาสตร์สาธารณสุข	1	0	1	0	1	1	0	0	0	2
วิทยาลัยประชากรศาสตร์	0	0	0	0	1	1	0	0	0	1
สถาบันวิจัยโลหะและวัสดุ	0	0	0	2	0	2	0	0	0	2
สถาบันวิจัยสภาวะแวดล้อม	0	0	0	1	0	1	0	0	0	1
สถาบันวิจัยเทคโนโลยีชีวภาพและวิศวกรรม	0	0	0	1	1	2	0	0	0	2
สถาบันวิจัยทรัพยากรทางน้ำ	0	0	0	2	0	2	0	0	0	2
สถาบันวิจัยสังคม	0	0	0	1	2	3	0	0	0	3
สถาบันเอเชียศึกษา	0	0	0	0	4	4	3	0	3	7
สถาบันบัณฑิตบริหารธุรกิจศศินทร์	0	0	0	0	1	1	0	0	0	1
	13	44	57	87	89	176	27	20	47	280

# Increasing Number of Post-doc



# Total International Research Forum since mid 2017-mid 2019







# Research **KPIs** 2560- 2562\*

*Based on Chula Internal Databases*


## KPI 2.2.1: Research **Impact** (number of output)



## KPI 2.2.2 Tier 1 publication (%)




# Extramural Funding (Gov. > Private)





# Chulalongkorn University Publications 2013-2018

■ Total Publication ■ Tier 1 ■ Q1





Evidences based on International Databases

# Chulalongkorn University SciVal Report 2019

## Research Intelligence

May 2019

Prepared by

**Alexander van Servellen**

[a.vanservellen@Elsevier.com](mailto:a.vanservellen@Elsevier.com)

Senior Consultant, Research Intelligence


Elsevier Singapore







# Annual Publication Output: 2013-2018 vs Benchmarking



NB: Number @ 22 May 2019


# Benchmarking

2013 to 2018



no subject area filter selected

## Top 10% Journal Percentile (CiteScore)



### Key Findings

- Chulalongkorn University has also surpassed Mahidol University and almost matched Universiti Malaya in terms of the percentage share of its papers published in top 10% journal percentile (based on CiteScore journal metric)


# Benchmarking

2013 to 2018



no subject area filter selected


Top 10% Citation Percentile (Field-Weighted)




## Key Findings

- Chulalongkorn University shows increasing percentage of it's papers in world top 10% citation percentile and surpassing Mahidol University in 2016.
- Universiti Malaya shows highest share of its papers in the top 10% citation percentile.

# Number of Publication in Top 25 Citation Percentile



# Number of Publication in Top 10 Citation Percentile




Overall we have **a positive trend of better in quality of research**

How should Chula further push for  
**more quality** and  
**more impact** researches ?



# CU Faculties Output, Growth & Impact

World Average = 1.0




## Key Findings

- CU's top faculties in terms of FWCI and journal quartiles are Faculties of Medicine, Allied Health and Dentistry
- High performance of Faculty Science is based largely on papers with more than 100 authors
- Faculty of Engineering produces high volume of papers, with below average impact. Improvement here will benefit CU.

# Chula by Subject area

World Average = 1.0



## Key Findings


- CU's key subject strengths include Medicine, Dentistry, Neuroscience and Psychology.
- While Physics & Astronomy show very high FWCI this is mainly based on high energy physics papers with > 1000 authors
- A large cluster of subjects show FWCI of between 0.80 and 1.00. Improving those will raise the overall impact of CU.

# Total Publication on **Clinical/Pre-Clinical Science** : MU>UM>CU

2013 to 2018



Clinical, pre-clinical and health




# Top 25% Journals on **Clinical/Pre-Clinical Science** : UM>CU>MU

2013 to 2018



Clinical, pre-clinical and health




# Top 10% Journals on **Clinical/Pre-Clinical Science** : $UM > CU = MU$

2013 to 2018




Clinical, pre-clinical and health



# Next Enhancing Strategies


for Higher and Sustainable Research Quality and Impact



**Official affiliation with international world-class research institutes in Thailand**

- NSTDA
- SEI, SEARCH, HIVNAT, AFRIM

# The 4 I's Strategies



## Top Talents Development

- Student exchange, Master, PhD, Post-doc
- Copaying partners: TRF, NSTDA, international U, CU faculties
- Current young staff development
- Recruiting top professors, researchers

## Infrastructure & Capacity Boost

- High end equipment for target research agenda
- Industrial-partner technology lab  
e.g. Big Data, AI Center

## Strategic Partner Matching

Top university strategic partners : 10/year (50 in 5 years)

- Joint research funding : 10 programs/year
- Double degree : 10/year (50 in 5 years)
- Forum, congress

## Big High Impact Programs



# Global Visibility Strategy

# International Website : [Research.chula.ac.th](https://Research.chula.ac.th)

+662-218-0240   [Research@chula.ac.th](mailto:Research@chula.ac.th)

[About us](#)   [FAQ](#)



## Chulalongkorn University

RESEARCH AND INNOVATION FOR SOCIETY

[TH](#)   [EN](#)   

## Strategy



### National Agenda

Research and Innovation to  
strengthen the country's  
economy and sustainability



### Regional and Global Agenda

Transforming the world with  
Research and Innovation



### Cutting Edge

Frontier in science, health and  
social research



### Partnerships

Collaborating partnership  
with domestic, international  
research institutes and  
private entities

## *New Funding Strategy to Support International Collaboration and Joint-Program*

# International research forum

Fund: 400,000 B

Activity:

1. To invite world class professors/ researchers
2. To host research forum –open session
3. To have round table discussion for setting up a collaboration, joint-program

*Connect, Collaborate for higher impact research*

## International Research Forum Fund



400,000 /forum

# Enhancing Chula **Individual** **Capacity** *and* **Visibility**



# eRM : [erm.research.chula.ac.th](http://erm.research.chula.ac.th)



Electronic Research Management



Academic  
Information



Master



Administration



Academic  
Promotion

## e-Database : One fits for all


- a Nice CV
- Academic promotion form
- HR report (tentative)
- Research Profile Searchable online





# eRM : erm.research.chula.ac.th

## Making a nice CV and a nice Professorship promotion form



### Electronic Research Management

Sign in as : Kiat Ruxrungtham

Personal Information

Home

Personal Information

Academic work

CV List

### Personal Information

Personal Details | Research Interest | Education | Training


#### Awards

+ Add

Edit

Delete

Given Year	Given By(Organization)
2015	Thailand Research Fund
2015	Thailand Research Fund
2011	Thailand Research Fund
2011	National Research Council
2007	Chulalongkorn University
2006	Royal College of Physicians,



### Electronic Research Management

Sign in as : Kiat Ruxrungtham

Academic Work

Home

Personal Information

Academic work

### Academic Work

Publication | Research Report | Other Academic Works | Book | Ban

#### Article

+ Add

Import Data

Double click for edit data.

For Delete : 

Delete

Select All

U

	Work Type	Author Name	Title of the Article	Title of the Journal	Publish Year
⚠		Boonpiyathad T., van de Veen W., Wirz ...	Role of Der p 1-specific B cells in immune ...	JOURNAL OF ALLERGY AND CLINICAL ...	2019
⚠		Boonpiyathad T., Sokolowska M., Morita ...	Der p 1-specific regulatory T-cell response...	Allergy: European Journal of Allergy a...	2019
⚠		Gatechompol S., Avihingsanon A., Apor...	Efficacy and improvement of lipid profile a...	AIDS RESEARCH AND THERAPY	2019
⚠		Teeraananchai S., Puthanakit T., Kerr SJ...	Attrition and treatment outcomes among ...	JOURNAL OF VIRUS ERADICATION	2019
⚠		Putcharoen O., Pleumkanitkul S., Chutin...	Comparable carotid intima-media thickne...	JOURNAL OF VIRUS ERADICATION	2019
⚠		Kanchanatawan B., Hemrungronj S., Thi...	Changes in Tryptophan Catabolite (TRYCA...	MOLECULAR NEUROBIOLOGY	2018
⚠		Han WM., Apornpong T., Kerr SJ., Hirans...	CD4/CD8 ratio normalization rates and lo...	AIDS RESEARCH AND THERAPY	2018



# Chula e-RM

## electronic Research Management



Prof.Kiat Ruxrungtham

Home

Projects & Monitoring

Evaluation Pipelines

Support & Award

Publication Incentive

Impact and Engagement Incentive

Awards

Management

Administration



ผลงานตีพิมพ์



รายการขอคำตีพิมพ์

Found 355 record(s).

No.	Items	Year	Database
1	High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers <b>DUP. 2</b> — collect date 2017-10-20 15:06:33 <b>Author(s)</b> — Boonpiyathad,T Meyer,N Moniuszko,M Sokolowska,... <a href="#">More</a> <b>Source</b> — ALLERGY	2017	ISI (Article)
2	Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis <b>DUP. 2</b> — collect date 2017-10-20 14:54:25 <b>Author(s)</b> — Teeraananchai,S Kerr,SJ Amin,J Ruxrungtham,K Law... <a href="#">More</a> <b>Source</b> — HIV MEDICINE	2017	ISI (Article)
3	Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway <b>DUP. 2</b> — collect date 2017-09-05 15:47:10 <b>Author(s)</b> — Kanchanatawan B. Sirivichayakul S. Thika S. Ruxrun... <a href="#">More</a> <b>Source</b> — Metabolic Brain Disease	2017	Scopus (Article)
4	Safety,Pharmacokinetics,and Antiviral Activity of a Novel HIV Antiviral,ABX464,in Treatment-Naïve HIV-Infected Subjects in a Phase 2 Randomized,Controlled Study <b>DUP. 2</b> — collect date 2017-10-20 14:56:00 <b>Author(s)</b> — Steens,JM Scherrer,D Gineste,P Barrett,PN Khuanch... <a href="#">More</a> <b>Source</b> — ANTIMICROBIAL AGENTS AND CHEMOTHERAPY	2017	ISI (Article)

# High Quality Articles and Books

## Supporting Writing & Publishing

How to provide  
better supporting system?



Register



Login

Professional development  
training for researchers — via  
workshops and online courses

Request a quote

About us

Good News  
Now goes live for All Chula  
Members including all students

To log in,  
please use your Chula account

We are delighted to announce our new website

If you were registered on our old website, please check your inbox for our email containing instructions on how to log in.  
Or if you're brand new to *Nature Masterclasses*, register today.

What's changed?

<https://masterclasses.nature.com>

# Clusters *What's New*



## Chulalongkorn University : Research Clusters

CU : Top Down Clusters

Aging

Smart Inclusive Society

Food, Water, Energy

Digital/Robotics



Health &  
Medicine Clusters

Tele-Health

Tropical Medicine

Health  
Frontier Research



Current  
Clusters

Food

Water

Advanced Material

Energy

Climate Change

ASEAN

Art & Culture



New  
Clusters

Bio-diversity

Genomics Medicine

Bio-refinery

Smart City

Energy Storage

Labour & Workforce

Inequality

**Remark** : Clusters can be “Changeable & Fade-out” if inefficiency.

# How Chula Making **Real Impact**?

Chula **ARi**

Chula **c**Tourism

Chula Cancer **Cure**

Chula Bio**Med**

Chula D**4**S


**C**Universe



**C2F + Global Chula + Proactive Partnerships + Grooming our staff + New Professor promotion system**  
will strongly enhance our research **quality** and **impact**



Chulalongkorn University Publications 2013-2018



How to be a  
**quality researcher ?**

# Your **Goal** pilots your **Future**



For career development ?  
For real impact researches ?

**Different Commitments**

**Different Determinations**

**Different Performances**

**Different Achievements**



# Leadership with hearty teamwork



[https://www.youtube.com/watch?  
v=5rOg4WfNDfM](https://www.youtube.com/watch?v=5rOg4WfNDfM)

*Don't fly alone*




The  
Wisdom of geese

# Matching a **mentor**



# How to build yourself up from scratch



**Funding** →

Intramural grant

Extramural grant

International

Star

RU

CE

Cluster

New mechanism:

High impact, multi-year

+ Project-based grant : Ratchada

# Commitment, Commitment, Commitment, is the key for the success of RU/CE



1. Focus : what is/are the main research area(s)
- 2. Regular scientific meeting**
- 3. Keeping up-to-date**
4. Come up with great research question and study design
5. Conduct the study with good quality
6. Promptly publish the results in good journals

# Types of Researches

1. Epidemiology
2. Clinical spectrum and characteristics
3. Natural History
4. Pathogenesis
5. Diagnostic tests, biomarkers
6. Therapeutics
7. Prevention

In **1 disease**, you/your team may study more than **1 category**

# R2R : How to make the study interesting and more impact ?

- Selecting disease(s) or scope of focus
  - Unique
  - Big number of patients
  - Reliability or quality of database
- Descriptive vs Hypothesis Driven
  - For example: NSIADs induce anaphylaxis is more common than most doctors have been aware of
- Identifying interesting findings to make a strong point for publication
- Writing a nice manuscript: Attractive title, abstract, conclusions, nice figures/tables, and a good discussion



# Anaphylaxis: a ten years inpatient retrospective study

Malee Techapornroong<sup>1,2</sup>, Krittapoom Akrawinthewong<sup>1</sup>, Wisit Cheungpasitporn<sup>1</sup> and Kiat Ruxrungtham<sup>3</sup>

Citation 37

Current IF =1.79

## Summary

**Background:** The actual incidence of anaphylaxis is unknown. Periodical study of the anaphylaxis in different countries will raise the awareness to improve further the prevention and care.

**Methods:** To investigate anaphylaxis among inpatients in the previous decade, we conducted a retrospective study of adult patients between 1992 and 2001 at a tertiary care center in Bangkok.

**Results:** Of 448,211 admissions, 80 events of anaphylaxis in 79 patients (0.017%) were found. The incidence had increased from 2.6 to 46 per 100,000 inpatients. Mean age $\pm$ SD was 36 $\pm$ 16 years-old, with an equal male:female ratio. Drugs, mainly antibiotics and non-steroidal anti-inflammatory agents, (48%) and food (31%) were the most common causes. Over-the-counter medication and multiple

## Introduction

The actual incidence of anaphylaxis is unknown. In the United States of America, it is at least 10 to 21 per 100,000 of population<sup>1</sup>. In Europe, two studies reported the incidence to be 3.2 cases per 100,000 person-years in Denmark<sup>2</sup> and 9.8 cases of out-of-hospital anaphylaxis per 100,000 person-years in Munich, Germany<sup>3</sup>). In Thailand, only few of retrospective studies in university-based hospitals have been conducted. One-year study of patients who attended the emergency department of an university hospital in Thailand found an incidence of up to 223 cases per 100,000 patients<sup>4</sup>. Another study from a university hospital in Bangkok showed an incidence of 55.45 cases per 100,000 admitted persons in 2004<sup>5</sup>. Periodical study of the anaphylaxis in various centers in different countries will further raise the awareness of changes in causative agents among each of the medical communities.



All Content



Search

[Advanced Search](#)

[Articles & Issues](#) ▾

[For Authors](#) ▾

[Journal Info](#) ▾

[Review Series Archive](#)

[More Periodicals](#) ▾

[< Previous Article](#)

**[October 2016](#)** Volume 65, Issue 4, Pages 432–438

[Next Article >](#)

## Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand

[Akarin Hiransuthikul](#), [Thanapoom Rattananupong](#), [Jettanong Klaewsongkram](#), [Pawinee Rerknimitr](#), [Marisa Pongprutthipan](#), [Kiat Ruxrungtham](#)  

**R2R**

***Retrospective Study***

By a research fellow at HIVNAT

**IF = 3.1**

**Citation = 18**

# Writing a Review Article:

*Must do, while conducting some original researches (it takes years)*

## THE LANCET

Volume 364, Issue 9428, 3–9 July 2004, Pages 69-82














---

Seminar

### HIV/AIDS in Asia

Kiat Ruxrungtham MD <sup>a</sup>, Tim Brown PhD <sup>b</sup>, Dr Praphan Phanuphak <sup>a</sup>  

# Review Articles: have higher citations

	Document title	Authors	Year	Source	Cited by
<input type="checkbox"/> 1	Ethics and best practice guidelines for training experiences in global health	Crump, J.A., Sugarman, J., Barry, M., (...), Sewankambo, N.K., Shao, J.F.	2010	American Journal of Tropical Medicine and Hygiene 83(6), pp. 1178-1182	174
	View abstract  View at Publisher Related documents	 			
<input type="checkbox"/> 2	Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010	Sungkanuparph, S., Techasathit, W., Utaipiboon, C., (...), Ruxrungtham, K., Phanuphak, P.	2010	Asian Biomedicine 4(4), pp. 515-528	74
	View abstract  Related documents				
<input type="checkbox"/> 3	Update on HIV/AIDS in Thailand	Ruxrungtham, K., Phanuphak, P.	2001	Journal of the Medical Association of Thailand 84(SUPPL. 1), pp. S1-S17	68
	View abstract  Related documents				
<input type="checkbox"/> 4	Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment	Hill, A., Ruxrungtham, K., Hanvanich, M., (...), Gatell, J., Ribera, E.	2007	Expert Opinion on Pharmacotherapy 8(5), pp. 679-688	62
	View abstract  View at Publisher Related documents				
<input type="checkbox"/> 5	Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: The recommendations of the thai AIDS society (TAS) 2008	Sungkanuparph, S., Anekthananon, T., Hiransuthikul, N., (...), Leechawengwongs, M., Ruxrungtham, K.	2008	Journal of the Medical Association of Thailand 91(12), pp. 1925-1936	50
	View abstract  Related documents				
<input type="checkbox"/> 6	Treatment of HIV infection with once-daily regimens	Permpalung, N., Putcharoen, O., Avihingsanon, A., Ruxrungtham, K.	2012	Expert Opinion on Pharmacotherapy 13(16), pp. 2301-2317	24
	View abstract  View at Publisher Related documents				

For High Impact Research :  
Seeking World Renowned Experts for  
Collaboration

PubMed.gov  
US National Library of Medicine National Institutes of Health

PubMed Advanced  
HBV AND Ruxrungtham

Format: Summary - Sort by: Most Recent - Per page: 20 -  
Send to -

Text availability  
Abstract  
Free full text  
Full text

Publication dates  
5 years  
10 years  
Custom range...

Species  
Humans  
Other Animals

Clear all  
Show additional filters

**Selected items**  
Items: 14

- B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy.**  
Crane M, Avihingsanon A, Rajasuriar R, Velayudham P, Iser D, Solomon A, Sebolao B, Tran A, Spelman T, Matthews G, Cameron P, Tangkijvanich P, Dore GJ, **Ruxrungtham K**, Lewin SR.  
J Infect Dis. 2014 Sep 1;210(5):745-51. doi: 10.1093/infdis/jiu119. Epub 2014 Feb 28.  
PMID: 24585898  
[Similar articles](#)
- CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy.**  
Giarda P, Avihingsanon A, Sasadeusz J, Audsley J, Marks P, Matthews G, **Ruxrungtham K**, Lewin SR, Crane M.  
Antivir Ther. 2014;19(4):429-33. doi: 10.3851/IMP2720. Epub 2014 Jan 16.  
PMID: 24430489  
[Similar articles](#)
- Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy.**  
Avihingsanon A, Apornpong T, Ramautarsing RA, Ubolyam S, Tangkijvanich P, Ananworanich J, Lange JM, Matthews G, Lewin SR, **Ruxrungtham K**; HIV-NAT 105 study team.  
Antivir Ther. 2014;19(1):41-9. doi: 10.3851/IMP2673. Epub 2013 Aug 23.  
PMID: 23970149  
[Similar articles](#)
- Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfecting individuals.**  
Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, Lewin SR, Sasadeusz J, Littlejohn M, Locarnini SL, **Ruxrungtham K**, Dore GJ.  
PLoS One. 2013 Apr 9;8(4):e61297. doi: 10.1371/journal.pone.0061297. Print 2013.

**HEPATOLOGY** AASL  
AMERICAN ASSOCIATION OF STUDY OF LIVER DISEASE

Impact factor: 13.246  
ISI Journal Citation Reports @ Ranking: 2016: 4/79 (Gastroenterology and Hepatology)

**IF 13**

- Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfecting with HIV and hepatitis viruses.**  
Andrade BB, Hullsiek KH, Boulware DR, Rupert A, French MA, **Ruxrungtham K**, Montes ML, Price H, Barreiro P, Audsley J, Sher A, Lewin SR, Sereti I; INSIGHT Study Group.  
J Infect Dis. 2013 May 1;207(9):1379-88. doi: 10.1093/infdis/jit033. Epub 2013 Jan 18.  
PMID: 23335804 **Free PMC Article**  
[Similar articles](#)
- Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfecting with HIV and hepatitis B virus.**  
Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, **Ruxrungtham K**, Saulynas M, Locarnini S, Thio CL.  
Clin Infect Dis. 2013 May;56(9):e87-94. doi: 10.1093/cid/cit002. Epub 2013 Jan 11.  
PMID: 23315316 **Free PMC Article**  
[Similar articles](#)
- Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfecting subjects initiating HBV-active antiretroviral therapy in Thailand.**  
Avihingsanon A, Matthews GV, Lewin SR, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Dore GJ, **Ruxrungtham K**.  
AIDS Res Ther. 2012 Mar 9;9(1):6. doi: 10.1186/1742-6405-9-6.  
PMID: 22405335 **Free PMC Article**  
[Similar articles](#)
- Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-HBV coinfection in Thailand.**  
Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanan N, Matthews GV, Dore GJ, Bowden S, Lange J, **Ruxrungtham K**.  
Antivir Ther. 2010;15(6):917-22. doi: 10.3851/IMP1645.  
PMID: 20834105  
[Similar articles](#)
- No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.**  
Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun S, Thantworasit P, Wightman F, Locarnini S, Matthews G, Dore GJ, **Ruxrungtham K**, Lewin SR.  
J Virol. 2010 Mar;84(6):2657-65. doi: 10.1128/JVI.02124-09. Epub 2010 Jan 6.  
PMID: 20053751 **Free PMC Article**  
[Similar articles](#)
- Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.**  
Chang JJ, Sirivichayakul S, Avihingsanon A, Thompson AJ, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, **Ruxrungtham K**, Lewin SR.  
J Virol. 2009 Aug;83(15):7649-58. doi: 10.1128/JVI.00183-09. Epub 2009 May 20.



**Prof. Sharon Lewin**  
Director, The Peter

- Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus-coinfecting individuals during combination therapy with tenofovir, or combination therapy.**  
Lewin SC, Sirivichayakul S, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, **Ruxrungtham K**, Perelson AS, Dore GJ.  
Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.  
PMID: 19115219 **Free PMC Article**  
[Similar articles](#)
- A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand.**  
Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapart P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, **Ruxrungtham K**, Dore GJ.  
Hepatology. 2008 Oct;48(4):1062-9. doi: 10.1002/hep.22462.  
PMID: 18697216  
[Similar articles](#)

**IF 4.6**

**Journal of Virology**  
AMERICAN SOCIETY FOR MICROBIOLOGY

**IF 6.2**

**The Journal of Infectious Diseases**  
IDSA hivma

**IF 2.2**

**Clinical Infectious Diseases**  
IDSA hivma

NA is not associated with disease status but is associated with drug resistance.  
P, Thompson A, Desmond P, Lewin SR, ...  
S, Revill PA.  
p.22386.

**World Class  
Research Institute**  
*How To ?*



# HIV-NAT

## Thai Red Cross AIDS Research Center



*Established* **1996**

**374** papers

Total citation = **6035**

h-Index = **37**



Full Staffs >100

**INSIGHT network**

**CTU, NIH**

**ACTG network, NIH**

**IRC (NIAID Influenza Research**

# HIV-NAT

## Thai Red Cross AIDS Research Center

### The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

AUGUST 27, 2015

VOL. 373 NO. 9

#### Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

The INSIGHT START Study

ABSTRACT

##### BACKGROUND

Data from randomized trials are lacking on the benefits and risks of initiating antiretroviral therapy in patients with asymptomatic human immunodeficiency virus (HIV) infection who have a CD4+ count of more than 350 cells per cubic millimeter.

##### METHODS

We randomly assigned HIV-positive adults who had a CD4+ count of more than 500 cells per cubic millimeter to start antiretroviral therapy immediately (immediate-initiation group) or to defer it until the CD4+ count decreased to 350 cells per cubic millimeter or until the development of the acquired immunodeficiency syndrome (AIDS) or another condition that dictated the use of antiretroviral therapy (deferred-initiation group). The primary composite end point was any serious AIDS-related event, serious non-AIDS-related event, or death from any cause.

##### RESULTS

A total of 4685 patients were followed for a mean of 3.0 years. At study entry, the median HIV viral load was 12,759 copies per milliliter, and the median CD4+ count was 651 cells per cubic millimeter. On May 15, 2015, on the basis of an interim analysis, the data and safety monitoring board determined that the study question had been answered and recommended that patients in the deferred-initi-

The members of the writing group (Jens D. Lundgren, M.D. [cochair], Abdel G. Babiker, Ph.D. [cochair], Fred Gordin, M.D. [cochair], Sean Emery, Ph.D., Birgit Grund, Ph.D., Shweta Sharma, M.S., Anchalee Avihingsanon, M.D., David A. Cooper, M.D., Gerd Falkenhauer, M.D., Josep M. Llibre, M.D., Jean-Michel Molina, M.D., Paula Munderi, M.D., Mauro Schechter, M.D., Robin Wood, M.D., Karin L. Klingman, M.D., Simon Collins, H. Clifford Lane, M.D., Andrew N. Phillips, Ph.D., and James D. Neaton, Ph.D. [INSIGHT PI]) of the INSIGHT START Study Group assume responsibility for the overall content and integrity of this article. The affiliations of the members of the writing group are listed in the Appendix. Address reprint requests to Dr. Lundgren at the Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark, or at jens.lundgren@regionh.dk.

Citation = 617

### THE LANCET Infectious Diseases

Volume 12, Issue 12, December

Citation = 92

NELM = 1

Lancet = 14

#### Articles

Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial

Thanyawee Puthanakit MD <sup>a, c</sup>, Vonthanak Saphonn MD <sup>e</sup>, Jintanat Ananworanich MD <sup>a, b, c</sup>, Pope Kosalaraksa MD <sup>f</sup>, Rawiwan Hansudewechakul MD <sup>g</sup>, Ung Vibol MD <sup>h</sup>, Stephen J Kerr PhD <sup>a, f</sup>, Suparat Kanjanavanit MD <sup>i</sup>, Chaiwat Ngampiyaskul MD <sup>j</sup>, Jurai Wongsawat MD <sup>k</sup>, Wicharn Luesomboon MD <sup>l</sup>, Nicole Ngo-Giang-Huong PhD <sup>m</sup>, Kea Chettra MD <sup>e</sup>, Theshinee Cheunyam RN <sup>a</sup>, Tulathip Suwarnlerk BNS <sup>a</sup>, Sasiwimol Ubolyam MSc <sup>a</sup>, Prof William T Shearer MD <sup>n</sup>, Prof Robert Paul PhD <sup>o</sup> ... Prof Kiat Ruxrungtham MD <sup>a, d, g, i</sup>

#### FULL TEXT ARTICLE

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial

Torsak Bunupuradah MD, Sasisopin Kiertiburanakul MD, Anchalee Avihingsanon MD, Ploenchana Chetchotisakd Prof, Malee Techapornroong MD, Niramon Leerattanapetch MD, Pacharee Kantipong MD, Chureeratana Bowonwatanuwong MD, Sukit Banchoangkit MD, Virat Klinbuaayem MD, Sripetcharat Mekwiwattanawong MD, Sireethom Nimitvilai MD, Supunnee Jirajariyavej MD, Wisit Prasithsirikul MD, Warangkana Munsakul MD, Sorakij Bhakeechep MD, Suchada Chaivooth MD, Praphan Phanuphak Prof, David A Cooper Prof, Tanakorn Apornpong MSc, Stephen J Kerr PhD, Sean Emery Prof and Kiat Ruxrungtham Prof

Lancet HIV, The, 2016-08-01, Volume 3, Issue 8, Pages e343-e350, Copyright © 2016 Elsevier Ltd



Lancet HIV, The  
Volume 3, Issue 8

Copyright © 2016 Elsevier Ltd

Get Full Text Elsewhere

### THE LANCET

Volume 364, Issue 9428, 3–9 July 2004, Pages 69–82

#### Seminar

#### HIV/AIDS in Asia

Kiat Ruxrungtham MD <sup>a</sup>, Tim Brown PhD <sup>b</sup>, Dr Praphan Phanuphak <sup>a, c, d, e</sup>

Show more

[https://doi.org/10.1016/S0140-6736\(04\)16593-8](https://doi.org/10.1016/S0140-6736(04)16593-8)

Get rights and content



# Social Science: Excellent Book Co-Publishing with Top 100 U

**SPRINGER**NATURE

≡ ホーム

Chula will facilitate and support !  
So contact deputy Dean + Chula Research Office

Leading the way in academic  
book publishing

Discover this unparalleled resource for students and researchers including  
the largest collection of scholarly eBooks.

Books

Our books are an unparalleled resource for students and researchers. The Springer eBook collection delivers complete access to the largest single publisher collection of scientific, technical, medical, humanities and social sciences publications available today.

Thousands of new reference works, monographs, briefs, proceedings, textbooks, and series are published every year. Explore them all on our individual imprint websites.

We have

300000 +  
Books

200 +  
Series



# Book Authors and Book Editors

[Overview](#)[Content types](#)[Submission process](#)

## Overview

*We invite you to join a community of world-renowned thought leaders who have partnered with Elsevier.*

Elsevier has a proud publishing history built on valued partnerships with authors to bring quality products to professionals and institutions throughout the world. Today, as an information analytics company on the forefront of digital innovation, Elsevier's commitment to these content partnerships has not wavered.

When you partner with Elsevier, you will work with a dedicated team of professionals to create content that is optimized for delivery in a variety of electronic formats, including potential publication on the leading full-text scientific database [ScienceDirect](#) <sup>↗</sup>, which reaches more than 16 million users worldwide, or [ClinicalKey](#), a medical search engine and database. When appropriate, books are also submitted to [Scopus](#) <sup>↗</sup>, the largest abstract and citation database of peer-reviewed literature: scientific journals, books, and conference proceedings.

# Research Integrity Issues

## Cardinal Sins on Research Misconducts

- 1. Plagiarism*
- 2. Fabrication*
- 3. Falsification*



# What are our goal of doing researches ?

**Academic  
Promotion  
Honor  
Funding**

**Improving  
Patient Dx & Care  
Improving QoL  
Preventing Diseases**

*May not be the right goals !*  
**May lead to misconduct**

**Should be  
the right ones !**

KOREAN STEM CELL SCANDAL

## Schatten: Pitt Panel Finds 'Misbehavior' but Not Misconduct

A University of Pittsburgh (UP) panel has declared stem cell researcher Gerald Schatten innocent of research misconduct in the South Korean stem cell debacle. But his failure to more closely oversee research with his name on it does make him guilty of "research misbehavior," according to a summary report released on 3 February.

In December, after the discovery of misdeeds by South Korean cloning researcher Woo Suk Hwang, UP medical school dean Arthur Levine set up a panel of six senior researchers to investigate the role of Schatten, who was presented as senior author on a paper purporting to show that disease-specific cell lines had



Photo opportunity. Gerald Schatten's (*right*) major contribution to the "Snuppy paper" was to suggest a professional photographer.



NATURE | NEWS



## US vaccine researcher sentenced to prison for fraud

The case of Dong-Pyou Han illustrates the uneven nature of penalties for scientific misconduct.

Sara Reardon

01 July 2015 | Updated: 01 July 2015



Science & Environment

## 'Fake research' comes under scrutiny

By Helen Briggs  
BBC News

© 27 March 2017



**Faculty/Department**  
**Strategy** for Excellence  
Both in **Research/Teaching &**  
**Services**

"Failure is an  
opportunity to grow"

## GROWTH MINDSET

"I can learn to do anything I want"

"Challenges help me to grow"

"My effort and attitude  
determine my abilities"

"Feedback is constructive"

"I am inspired by the success of others"

"I like to try  
new things"

"Failure is the  
limit of my abilities"

## FIXED MINDSET

"I'm either good at it or I'm not"

"My abilities are unchanging"

"I don't like  
to be challenged"

"I can either do it,  
or I can't"

"My potential is predetermined"


"When I'm frustrated,  
I give up"

"Feedback and criticism  
are personal"

"I stick to what I know"



# Strategies for being a Excellent Department or Faculty



## Key Success Factors


- Mindset
- Commitment
- Smart management
- Teamwork Spirit of Geese

## Smart policy: 2-3 tracks

- Good teachers, Services
- Good researchers or combined

## Smart Management

- Boosting Income: Fund raising, Excellent services
- Services — strengthening by part-time ex-fellows/experts



# Being a good researchers with great leadership





# TIME !

## Management


- Your own “**Time protection**” in 7 days x 24 h
- Keep promise to the **milestones & timelines**





New Staffs  
<5 yrs in CU



CU New Faculty 2561 



196 

# When you need info or help:

Website

[www.research.chula.ac.th](http://www.research.chula.ac.th)

Facebook

สำนักบริหารวิจัย-จุฬาฯ

eRM

<https://portal.research.chula.ac.th/>  
*in development*

InnoHub

<http://innovationhub.chula.ac.th/>

Contact Us

Email: [research@chula.ac.th](mailto:research@chula.ac.th)

Call 02-218-0212, 02-218-0240

# Feel Free to **Contact US**

## Vice and assistance Presidents



ศ. นพ. เกียรติ รัชช์รุ่งธรรม

[kiat.r@chula.ac.th](mailto:kiat.r@chula.ac.th) Tel: 095-369-9656

**Line** ID: kiat.rux



ศ. นพ. ยิ่งยศ อวิหิงसानนท์

[yingyos.a@gmail.com](mailto:yingyos.a@gmail.com)

Tel: 086-774-5050



รศ. ดร. วิทยา กุลสมบูรณ์.

[vithaya.k@chula.ac.th](mailto:vithaya.k@chula.ac.th)







# Research For Society